Overall rank by patents
#15,492
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Neumora Therapeutics, Inc.
USPTO PatentsView assignee record - 19 granted patents across 11 technology areas, active 2023–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: G16H (HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA).
19
Total patents granted
11
CPC technology areas
26.8
Avg claims per patent
-
5-year filing velocity
The verdict
Neumora holds 19 US patents across 11 technology areas, rank #15,492 of 50,000 tracked assignees.
- #15,492
- of 50,000 US assignees by volume
- Top 5%
- by Innovation Score (57.1/100)
- 26.8
- avg claims per patent
Portfolio overview
Neumora Therapeutics, Inc. has been granted 19 US utility patents between 2023 and 2025, placing Neumora Therapeutics, Inc. at rank #15,492 across all assignees tracked by PlainPatent. This portfolio spans 11 distinct Cooperative Patent Classification (CPC) subclasses, averaging 26.8 claims per patent with primary concentration in G16H (HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA). As a US Corporation, Neumora Therapeutics, Inc. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 57.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2023 through 2025, with 19 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Neumora Therapeutics, Inc.'s 26.8 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 11 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Neumora Therapeutics, Inc. against peers pursuing similar technology classes.
How does Neumora compare?
Granted US patents 2015–2025 versus the largest corporate holders, this company marked ◀
- Samsung
SAMSUNG ELECTRONICS CO., LTD.
106,890 patents
- International Bus…
International Business Machines Corporation
72,926 patents
- Canon 34,378
Canon Kabushiki Kaisha
34,378 patents
- LG 32,607
LG ELECTRONICS INC.
32,607 patents
- Taiwan Semiconduc… 31,041
TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD.
31,041 patents
- Apple 30,560
Apple Inc.
30,560 patents
- Qualcomm Incorpor… 30,354
QUALCOMM Incorporated
30,354 patents
- Intel 27,498
Intel Corporation
27,498 patents
- Neumora Therapeut… ◀ 19
Neumora Therapeutics, Inc.
19 patents
What this shows Neumora holds 19 patents, placing it at rank #15,492 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.
Neumora's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
57 Top 5% higher than 95% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
USPTO utility patent grants by year · 2023–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2023 | 7 | 36.8% |
| 2024 | 9 | 47.4% |
| 2025 | 3 | 15.8% |
Which technologies does Neumora Therapeutics, Inc. patent most?
Top 11 of 11 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Frequently Asked Questions
How many patents does Neumora Therapeutics, Inc. hold?
Neumora Therapeutics, Inc. holds 19 US granted patents filed between 2023 and 2025, spanning 11 technology areas.
What is Neumora Therapeutics, Inc.'s Innovation Score?
Neumora Therapeutics, Inc. has an Innovation Score of 57.1 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Neumora Therapeutics, Inc. focus on?
Neumora Therapeutics, Inc.'s top technology area is G16H (HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA) with 13 patents. The company has filed patents in 11 CPC subclasses total.
Is Neumora Therapeutics, Inc.'s patent filing rate increasing or decreasing?
Insufficient historical data is available to calculate a velocity trend for Neumora Therapeutics, Inc..
What does claim depth mean for Neumora Therapeutics, Inc.'s patents?
Neumora Therapeutics, Inc.'s patents average 26.8 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Neumora Therapeutics, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
Guides to patent portfolio analysis
How to use this portfolio
Neumora's 19 grants land it in the top 5% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Neumora ranks #15,492 of 50,000. Top 50 holders
- Most of this portfolio concentrates in G16H - see who else leads that technology area. G16H leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Explore the patent dataset
G16H technology
Neumora Therapeutics, Inc.'s primary CPC class, all holders and yearly trends
Top 50 patent holders
See where Neumora Therapeutics, Inc. ranks among the largest US patent assignees
All technology classes
Browse every CPC technology area by patent activity
How the score works
The four dimensions behind the Innovation Score
Related
Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Data sources used on this page
- USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
- Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
- USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov
